Cancer Drugs Fund requires further reform
Reliance on “real world” observational data undermines evidence base for clinical practice.
Príomhchruthaitheoirí: | Grieve, R, Abrams, K, Claxton, K, Goldacre, B, James, N, Nicholl, J, Parmar, M, Parker, C, Sekhon, J, Smeeth, L, Spiegelhalter, D, Sculpher, M |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
BMJ Publishing Group
2016
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Huang Shu Yin funded for further study
de réir: Kwong Wah, Yit Poh
Foilsithe / Cruthaithe: (2017) -
Huang Shu Yin Funded For Further Study
de réir: Kwong Wah, Yit Poh
Foilsithe / Cruthaithe: (2017) -
MRE in NAFLD: promising but further validation is required
de réir: Ryan, J, et al.
Foilsithe / Cruthaithe: (2018) -
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
de réir: Morrell, L, et al.
Foilsithe / Cruthaithe: (2018) -
Bladder cancer: issues requiring further research
de réir: I. A. Rozhkov, et al.
Foilsithe / Cruthaithe: (2024-09-01)